Previous 10 | Next 10 |
Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , May 5, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutic...
NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces their featured corporate interviews for two episodes, 459 and 460, that will air on Newsmax and the FOX Business Network. Newsmax TV airs Episode 459 Saturday, April 22, 2023, at 3:30 PM...
Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference PR Newswire A scientific poster highlighting a novel pharmacologic property of oral ibezapolstat for C. difficile Infection likely related to i...
NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a premier business television show, announces their featured guests' lineups on shows 452, 457, and 458. Each show is to air across New to The Street's syndicated televised platforms on Newsmax and the FOX Bus...
FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference PR Newswire FDA has accepted an Interim Analysis Plan for an IDMC to assess clinical outcome when 36 patients are enrolled ...
NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- FMW Media's business TV show, New to The Street, announces signing Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) ("Acurx") to an additional six-month media contract for filming and broadcasting tailored interviews, commercials, and digital billboa...
2023-03-16 14:20:36 ET Acurx Pharmaceuticals, Inc. (ACXP) Q4 2022 Earnings Conference Call March 16, 2023 08:00 ET Company Participants Robert Shawah - Co-Founder & Chief Financial Officer David Luci - President & Chief Executive Officer Conference Call...
2023-03-16 07:10:40 ET Acurx Pharmaceuticals press release ( NASDAQ: ACXP ): Q4 GAAP EPS of -$0.28 beats by $0.15 . The Company ended the year, with cash totaling $9.1 million compared to $13.0 million as of December 31, 2021. For further details see: Acurx P...
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , March 16, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a cli...
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , March 6, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical...
News, Short Squeeze, Breakout and More Instantly...
Acurx Pharmaceuticals Inc. Company Name:
ACXP Stock Symbol:
NASDAQ Market:
Acurx Pharmaceuticals Inc. Website:
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome PR Newswire STATEN ISLAND, N.Y. , July 17, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:...
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , July 16, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference PR Newswire Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including inc...